Wuppertal, Germany

Thomas Neubauer

This inventor holds 17 USPTO granted patents and 6 published patent applications and 6 EPO patents, primarily in Triazole Derivatives. Top assignees: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft. Active years: 2018-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Thomas Neubauer. Retrieved from https://idiyas.com/inventor/thomas-neubauer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 17 

% Patents Active = 47.1

 

Average Co-Inventor Count = 11.5

ph-index = 3

Forward Citations = 16(Granted Patents)


Company Filing History:


Years Active: 2018-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
Triazole Derivatives
MASP Inhibitors
Prolyl Endopeptidase Inhibitors
Amine Substituted
Pyridinyltriazole
Phenyltriazole
Hydroxyalkyl
Fluoroalkyl
Substituted Compounds
Derivatives
Heteroaryltriazole
Prodrugs
17 patents (USPTO):Explore Patents

Title: Thomas Neubauer: Innovator in Medical Compounds

Introduction

Thomas Neubauer is a prominent inventor based in Wuppertal, Germany. He has made significant contributions to the field of medical research, particularly in the development of innovative compounds for treating various diseases. With a total of 17 patents to his name, Neubauer's work has the potential to impact the medical community profoundly.

Latest Patents

Among his latest patents is the invention of MASP inhibitory compounds and their uses. This invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives. The patent outlines processes for the preparation of these compounds and their applications in treating and preventing diseases, particularly renal and cardiovascular disorders, as well as ischemia-reperfusion injuries. Another significant patent involves substituted [1,2,4]triazolo[4,3-A]pyrazines as prolyl endopeptidase inhibitors. This invention focuses on prolyl endopeptidase (PREP) inhibitors that contain a condensed 2,4-dihydro-3H-1,2,4-triazol-3-one ring system. The patent details methods for producing these inhibitors and their use in treating inflammatory lung diseases, such as Chronic Obstructive Pulmonary Disease (COPD).

Career Highlights

Throughout his career, Thomas Neubauer has worked with notable companies, including Bayer Pharma Aktiengesellschaft and Bayer Aktiengesellschaft. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in medical treatments.

Collaborations

Neubauer has collaborated with esteemed colleagues, including Heiko Schirmer and Peter Kolkhof. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise in the field of medical research.

Conclusion

Thomas Neubauer's contributions to the field of medical innovation are noteworthy, with a focus on developing compounds that address critical health issues. His patents reflect a commitment to improving treatment options for various diseases, showcasing his role as a significant inventor in the medical community.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…